InstantGMP sets AI governance plan for GxP records ahead of EU deadline

InstantGMP outlined how it is governing AI features in electronic batch records and quality systems before the EU AI Act’s high-risk compliance dates now pushed into 2027 and 2028. The company says its approach keeps AI-assisted GxP records inside the same audit trail, validation and data integrity controls that inspectors already expect.

Why it matters: - AI is moving into regulated manufacturing workflows, but GxP records still have to pass inspection under long-standing data integrity and electronic record rules. - InstantGMP is framing AI governance as a platform issue, not an add-on, for pharmaceutical, biotech and medical device manufacturers. - The company’s stance reflects a broader question for the industry: whether AI-generated observations, deviation flags and trend analyses can withstand FDA or EMA scrutiny.

What happened: - InstantGMP detailed its AI governance approach for GxP electronic records ahead of the 2026 PDA/FDA Joint Regulatory Conference. - The announcement centers on AI-assisted quality management and electronic batch records. - The company said it began an Annex IV-aligned gap analysis and technical documentation effort for AI-enabled features before the original 2026 compliance deadline. - Dr. Richard Soltero, president of InstantGMP, said manufacturers do not need to wait until December 2027 to decide whether an AI feature belongs in a validated record.

The details: - In May 2026, European Union institutions reached a provisional political agreement on the European Commission’s Digital Omnibus package. - That agreement postponed the EU AI Act’s high-risk compliance deadline for standalone AI systems to December 2, 2027. - The same delay pushed the deadline for AI embedded in already-regulated products, such as medical devices, to August 2028. - Annex IV of the EU AI Act requires technical documentation covering system design, data governance, risk management and human oversight. - InstantGMP said its AI features are scoped narrowly, including anomaly and deviation flagging for human review. - The company said AI-assisted entries in its QMS and EBR flow through the same audit trail as every other record. - InstantGMP said its AI outputs support the record and do not replace the reviewer. - The company said its platform natively integrates EBR, QMS, MES and LIMS functions in a single pre-validated system. - InstantGMP said that setup keeps records attributable, legible, contemporaneous, original and accurate, with traceability back to source data and the operator. - The company said its platform serves manufacturers in pharmaceuticals, biotechnology, dietary supplement and nutraceutical, and medical device production. - InstantGMP also said contract manufacturers managing GxP records for multiple clients can use the platform. - InstantGMP said it has been publishing analysis throughout 2026 on FDA’s 7-Step AI Credibility Framework, Annex 22, FDA warning letters, validation, agentic AI, root cause analysis and AI quality management. - The company said its platform is pre-validated to 21 CFR Part 11, GAMP 5, ISO 13485 and EMEA Annex 11 standards.

Between the lines: - The EU deadline delay gives manufacturers more time, but it does not remove the need to prove that AI-assisted records remain trustworthy and reviewable. - InstantGMP is positioning itself as a vendor that built those controls into the core platform before regulators force the issue. - The company is also betting that human-in-the-loop AI will face less validation burden than more autonomous systems.

What’s next: - InstantGMP said it will bring its AI governance approach into discussions at the 2026 PDA/FDA Joint Regulatory Conference. - The company is encouraging manufacturers to schedule demos or contact its team ahead of the conference. - As AI use expands in quality systems and batch documentation, the validation standard for these tools is likely to remain a live regulatory topic.

The bottom line: - InstantGMP is making the case that AI in regulated manufacturing must be validated, auditable and human-reviewed from the start, not retrofitted after regulators catch up.